Dacomitinib
- Generic Name
- Dacomitinib
- Brand Names
- Vizimpro
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25ClFN5O2
- CAS Number
- 1110813-31-4
- Unique Ingredient Identifier
- 2XJX250C20
- Background
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains.
...
- Indication
Dacomitinib is indicated as the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as verified by an FDA-approved test.
...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20605
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
- Conditions
- Interventions
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT05271916
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Fondazione Ricerca Traslazionale
- Target Recruit Count
- 170
- Registration Number
- NCT04811001
- Locations
- 🇮🇹
IRCCS Istituto Tumori "Giovanni Paolo II", Bari, BA, Italy
🇮🇹Istituto Toscano Tumori Ospedale San Donato, Arezzo, AR, Italy
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Peking Union Medical College
- Target Recruit Count
- 82
- Registration Number
- NCT04768491
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Central Nervous System(CNS) Efficacy of Dacomitinib
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT04675008
- Locations
- 🇰🇷
Jong-Mu Sun, Seoul, Korea, Republic of
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT04609319
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 272
- Registration Number
- NCT04575415
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 101
- Registration Number
- NCT04511533
- Locations
- 🇮🇳
Artemis hospital, Gurugram, Haryana, India
🇮🇳Apex Wellness Hospital, Nashik, Maharashtra, India
🇮🇳Gujarat Hospital - Gastro & Vascular Centre, Surat, Gujarat, India
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04504071
- Locations
- 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China
An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 50
- Registration Number
- NCT04339829
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.